PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31254971-1	2019	Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT).	3-carboxamido-4-hydroxynaltrexone	14-25	COMM domain containing 3	Homo sapiens	27-30
34887529-0	2022	Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.	3-carboxamido-4-hydroxynaltrexone	83-94	insulin	Homo sapiens	0-7
31919994-2	2020	As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers.	3-carboxamido-4-hydroxynaltrexone	103-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
31919994-2	2020	As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers.	3-carboxamido-4-hydroxynaltrexone	272-283	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	3-28
31919994-2	2020	As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers.	3-carboxamido-4-hydroxynaltrexone	272-283	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
31919994-5	2020	CYP3A4 inhibition is predicted to have a weak effect on samidorphan exposure and negligible effect on olanzapine exposure.	3-carboxamido-4-hydroxynaltrexone	56-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
31919994-6	2020	CYP3A4 induction is predicted to reduce both samidorphan and olanzapine exposure.	3-carboxamido-4-hydroxynaltrexone	45-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
31919994-2	2020	As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers.	3-carboxamido-4-hydroxynaltrexone	103-114	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	3-28
31040679-2	2019	Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major depressive disorder.	3-carboxamido-4-hydroxynaltrexone	110-121	COMM domain containing 3	Homo sapiens	123-126
31463821-0	2019	Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age.	3-carboxamido-4-hydroxynaltrexone	44-55	renin binding protein	Homo sapiens	131-134
30102427-1	2019	Buprenorphine/samidorphan combination (BUP/SAM) is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder.	3-carboxamido-4-hydroxynaltrexone	14-25	COMM domain containing 3	Homo sapiens	39-42
30102427-2	2019	BUP/SAM is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist added to address the abuse and dependence potential of buprenorphine.	3-carboxamido-4-hydroxynaltrexone	133-144	COMM domain containing 3	Homo sapiens	0-3
30102427-10	2019	These findings indicate that samidorphan substantially reduces the abuse potential of buprenorphine in the BUP/SAM combination.	3-carboxamido-4-hydroxynaltrexone	29-40	COMM domain containing 3	Homo sapiens	107-110